Does the media prefer MNPR or LFCR?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Monopar Therapeutics' score of 0.65 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFCR or RLMD?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Relmada Therapeutics' score of 0.65 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFCR or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Allogene Therapeutics' score of 0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RGNX or LFCR?

In the previous week, REGENXBIO had 8 more articles in the media than Lifecore Biomedical. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat REGENXBIO's score of 0.21 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRMD or LFCR?

In the previous week, CorMedix and CorMedix both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 0.89 beat CorMedix's score of 0.67 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifecore Biomedical (LFCR) Competitors

$4.69 +0.01 (+0.21%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.70 +0.01 (+0.21%)

As of 04:34 AM Eastern

Compare

LFCR vs. MNPR, RLMD, ALLO, RGNX, and CRMD

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include Monopar Therapeutics (MNPR), Relmada Therapeutics (RLMD), Allogene Therapeutics (ALLO), REGENXBIO (RGNX), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Lifecore Biomedical compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Monopar Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Lifecore Biomedical's return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Lifecore Biomedical	-25.43%	N/A	-14.40%

Monopar Therapeutics currently has a consensus price target of $108.75, indicating a potential upside of 2.69%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 38.59%. Given Lifecore Biomedical's higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Monopar Therapeutics had 4 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Monopar Therapeutics' score of 0.65 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Lifecore Biomedical	$128.87M	1.37	-$35.26M	-$0.94	N/A

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Monopar Therapeutics and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Relmada Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Lifecore Biomedical has higher revenue and earnings than Relmada Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.37	-$35.26M	-$0.94	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Lifecore Biomedical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Lifecore Biomedical currently has a consensus target price of $6.50, suggesting a potential upside of 38.59%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 140.00%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Lifecore Biomedical's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	N/A	-14.40%
Relmada Therapeutics	N/A	-71.22%	-64.46%

In the previous week, Relmada Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Relmada Therapeutics' score of 0.65 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Lifecore Biomedical beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Allogene Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Allogene Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Lifecore Biomedical's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	N/A	-14.40%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

In the previous week, Allogene Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Allogene Therapeutics' score of 0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 38.59%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 381.48%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Lifecore Biomedical has higher revenue and earnings than Allogene Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.37	-$35.26M	-$0.94	N/A
Allogene Therapeutics	$20K	30,545.78	-$190.89M	-$0.77	N/A

Summary

Allogene Therapeutics beats Lifecore Biomedical on 10 of the 17 factors compared between the two stocks.

How does Lifecore Biomedical compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

REGENXBIO currently has a consensus price target of $23.82, indicating a potential upside of 130.80%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 38.59%. Given REGENXBIO's stronger consensus rating and higher possible upside, equities research analysts plainly believe REGENXBIO is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

REGENXBIO has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Lifecore Biomedical has a net margin of -25.43% compared to REGENXBIO's net margin of -330.23%. Lifecore Biomedical's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Lifecore Biomedical	-25.43%	N/A	-14.40%

In the previous week, REGENXBIO had 8 more articles in the media than Lifecore Biomedical. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat REGENXBIO's score of 0.21 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has lower revenue, but higher earnings than REGENXBIO. Lifecore Biomedical is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.13	-$193.88M	-$5.60	N/A
Lifecore Biomedical	$128.87M	1.37	-$35.26M	-$0.94	N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

REGENXBIO and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

CorMedix presently has a consensus target price of $14.86, suggesting a potential upside of 90.97%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 38.59%. Given CorMedix's stronger consensus rating and higher probable upside, research analysts clearly believe CorMedix is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lifecore Biomedical	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, CorMedix and CorMedix both had 2 articles in the media. Lifecore Biomedical's average media sentiment score of 0.89 beat CorMedix's score of 0.67 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has a net margin of 45.25% compared to Lifecore Biomedical's net margin of -25.43%. CorMedix's return on equity of 45.57% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Lifecore Biomedical	-25.43%	N/A	-14.40%

34.2% of CorMedix shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CorMedix has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

CorMedix has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.96	$163.05M	$2.13	3.65
Lifecore Biomedical	$128.87M	1.37	-$35.26M	-$0.94	N/A

Summary

CorMedix beats Lifecore Biomedical on 12 of the 15 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$175.54M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-4.99	20.49	27.07	23.95
Price / Sales	1.37	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	11.17	7.92	10.62	6.14
Net Income	-$35.26M	$23.81M	$3.60B	$331.74M
7 Day Performance	1.74%	-1.09%	-1.26%	-1.82%
1 Month Performance	-15.34%	2.56%	1.07%	-1.45%
1 Year Performance	-37.13%	42.16%	23.63%	16.32%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.7938 of 5 stars	$4.69 +0.2%	$6.50 +38.6%	-37.4%	$175.54M	$128.87M	N/A	690	Positive News
MNPR Monopar Therapeutics	1.3151 of 5 stars	$99.79 -3.4%	$108.75 +9.0%	+127.8%	$692.21M	N/A	N/A	10	News Coverage High Trading Volume
RLMD Relmada Therapeutics	2.3521 of 5 stars	$6.21 -3.7%	$12.00 +93.2%	+766.6%	$676.54M	N/A	N/A	10
ALLO Allogene Therapeutics	1.9258 of 5 stars	$1.85 -4.1%	$8.52 +360.7%	+41.6%	$666.15M	$20K	N/A	310	Positive News
RGNX REGENXBIO	3.6208 of 5 stars	$12.29 -3.6%	$23.82 +93.8%	+26.5%	$659.15M	$170.44M	N/A	370

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. MNPR, RLMD, ALLO, RGNX, and CRMD

How does Lifecore Biomedical compare to Monopar Therapeutics?

Summary

How does Lifecore Biomedical compare to Relmada Therapeutics?

Summary

How does Lifecore Biomedical compare to Allogene Therapeutics?

Summary

How does Lifecore Biomedical compare to REGENXBIO?

Summary

How does Lifecore Biomedical compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. MNPR, RLMD, ALLO, RGNX, and CRMD

How does Lifecore Biomedical compare to Monopar Therapeutics?

Which has more volatility & risk, MNPR or LFCR?

Is MNPR or LFCR more profitable?

Do analysts recommend MNPR or LFCR?

Does the media prefer MNPR or LFCR?

Which has stronger valuation & earnings, MNPR or LFCR?

Do institutionals and insiders believe in MNPR or LFCR?

Summary

How does Lifecore Biomedical compare to Relmada Therapeutics?

Which has preferable valuation & earnings, LFCR or RLMD?

Which has more volatility and risk, LFCR or RLMD?

Do analysts recommend LFCR or RLMD?

Is LFCR or RLMD more profitable?

Does the media refer more to LFCR or RLMD?

Do institutionals & insiders hold more shares of LFCR or RLMD?

Summary

How does Lifecore Biomedical compare to Allogene Therapeutics?

Do insiders & institutionals believe in LFCR or ALLO?

Is LFCR or ALLO more profitable?

Which has more volatility & risk, LFCR or ALLO?

Does the media refer more to LFCR or ALLO?

Do analysts rate LFCR or ALLO?

Which has better valuation and earnings, LFCR or ALLO?

Summary

How does Lifecore Biomedical compare to REGENXBIO?

Do analysts prefer RGNX or LFCR?

Which has more volatility & risk, RGNX or LFCR?

Is RGNX or LFCR more profitable?

Does the media favor RGNX or LFCR?

Which has preferable valuation & earnings, RGNX or LFCR?

Do insiders and institutionals hold more shares of RGNX or LFCR?

Summary

How does Lifecore Biomedical compare to CorMedix?

Do analysts recommend CRMD or LFCR?

Does the media prefer CRMD or LFCR?

Is CRMD or LFCR more profitable?

Do insiders and institutionals hold more shares of CRMD or LFCR?

Which has more volatility & risk, CRMD or LFCR?

Which has better valuation & earnings, CRMD or LFCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools